OBI Pharma (4174 TWO) stock market data APIs
NT$56.8
-0.4(-0.7%)
as of January 22, 2025
OBI Pharma Financial Data Overview
Price chart is built with
Anychart
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.
Prev. Close
57.2
Open
56.8
Volume
534 K
High
57.6
Low
56
52 wk Range
55-92.9
Market Cap
15 042 M
Shares Outstanding
263 M
Revenue
58 046 K
EPS
-2.52
Beta
0.936
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OBI Pharma data using free add-ons & libraries
Get OBI Pharma Fundamental Data
OBI Pharma Fundamental data includes:
- Net Revenue: 58 046 K
- EBITDA: -2 063 065 984
- Earnings Per Share: -9
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-03-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OBI Pharma News
New
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
OBI Pharma Inc. First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody - drug conjugate (ADC) targeting TROP2. Dosing of first patient in the Phase 1/2 clinical trial e...
OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer
OBI Pharma Inc. Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally. She ...
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
OBI Pharma Inc. Poster Presentations to highlight the latest research on OBI-999’s (anti-Globo H ADC) synergistic anti-tumor effect in combination with pembrolizumab and OBI’s development of CAR ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
